ARA 290 – 16MG per vial

ARA 290 – Clinical Test Expectation in Human Subjects

Short Description: ARA 290, an erythropoietin-derived polypeptide, exhibits anti-inflammatory and immunomodulatory properties that aim to reduce inflammation and mitigate neuropathic pain.

ARA 290 is a synthetic polypeptide derived from erythropoietin, known for its analgesic and tissue-protective effects in a range of conditions, including diabetes and cancer. This peptide’s ability to alleviate pain is attributed to its significant anti-inflammatory and immunomodulatory capabilities, primarily through its interaction with the innate repair receptor (IRR), which helps decrease inflammation and ultimately reduce neuropathic pain. However, the full range of mechanisms and pathways through which ARA 290 exerts its analgesic effects is not completely understood.

This study focuses on the potential of ARA 290 to directly engage peripheral nociceptors and influence pain sensation by acting on specific receptors. Utilizing techniques such as calcium imaging, cell culture experiments, and behavioral assessments, our findings revealed that ARA 290 effectively inhibited the activity of the TRPV1 (transient receptor potential vanilloid 1) channel. This inhibition also resulted in a reduction of mechanical hypersensitivity induced by capsaicin, a known pain trigger. Our research proposes that ARA 290 may serve as a novel antagonist for the TRPV1 channel.

The implications of this discovery are substantial, both for the advancement of pain management therapies leveraging this peptide and for enhancing our comprehension of how the immune system interacts with the peripheral nervous system.